ESR1 and breast cancer: Accounting for approximately 1 in 5 breast cancers, TNBC lacks the three most commonly targeted receptors, ER, PR and HER2, and is characterised by an aggressive and invasive phenotype with poor patient survival due to a lack of effective therapeutic targets3,46.